In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
16 authors.
Alexander ConaCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0009-0009-8065-9414 Evan NewboldCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0000-0001-7497-7824 Deniz KesmenCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0009-0006-7150-2800 Rajiv SnapeCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0009-0002-2511-8665 Jessica DannerCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.
Nicholas WhiteCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.
William BordenCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.
Abigail IsesonCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.
Steven J SchanzCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0000-0001-8359-5350 Devin Chandler-MilitelloCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0000-0002-3766-8368 Xiaojie LiCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.
Jose C CanoCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.
John N MarianiCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0000-0002-0287-8461 Maiken NedergaardCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0000-0001-6502-6031 Abdellatif BenraissCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0000-0002-0325-6234 Steven A GoldmanCenter for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.ORCID 0000-0002-5498-4303 Funding
TRANSCRIPTIONAL DETERMINANTS OF THE FATE TRAJECTORIES OF SINGLE HUMAN GLIAL PROGENITOR CELLS IN RESPONSE TO DEMYELINATION IN VIVOR01NS110776 · NINDS · UNIVERSITY OF ROCHESTER · PI GOLDMAN, STEVEN ALAN · 2019 to 2023
$1.8MCell-intrinsic and contextual determinants of aging by human glial progenitor cellsR01AG072298 · NIA · UNIVERSITY OF ROCHESTER · PI GOLDMAN, STEVEN ALAN · 2021 to 2025
$1.6MNIA NIH HHS R01 AG072298NINDS NIH HHS R01 NS110776
6 · The paper itselfAbstract
To establish a means of efficiently transducing human glial progenitor cells (hGPCs) in vivo with therapeutic transgenes, we targeted PDGFRA-driven Cre-recombinase expressing hGPCs in human glial chimeric mice with a library of capsid-modified, recombination-reported adeno-associated viruses (AAVs). PCR screening for gliotropic viral capsid sequences, filtered against visceral organs, identified a set of AAV5-based vectors that preferentially infected human GPCs and/or their derived astrocytes and oligodendrocytes in vivo, with minimal systemic infection. To maximize the intracerebral distribution of these viruses while minimizing their dosing and extracerebral spread, we paired their intracisternal delivery with systemic hypertonicity. This method exploited intracerebral glymphatic flow to bypass the blood-brain barrier, delivering AAV directly into the brain parenchyma. Glymphatic delivery of capsid-modified AAV5s, evolved on human GPCs in vivo, thus enables efficient, brain-wide transgene delivery to human glia and their progenitors in the adult brain, with minimal off-target transduction.
Indexed as
adeno-associated viruscapsid evolutiongene therapyglymphatic systemhuman glial chimerasHuman glial progenitor cellsneurological gene therapyviral gene therapy
Identifiers
PMID40631159
PMCPMC12236521
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390